- Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101
- ESO-101, EsoCap’s lead product candidate, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate
- In a previous trial, EsoCap’s proprietary and unique targeted application technology for the upper gastrointestinal tract was shown to dramatically increase mucosal contact time and was well accepted
EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, reports the first patient in the Phase II ACESO trial has been dosed. The randomized, placebo-controlled, double-blind trial will evaluate the efficacy, tolerability and safety of ESO-101 in 42 adult patients with active eosinophilic esophagitis (EoE), in four European countries. Patients will be randomized 2:1 and will be treated for 28 days.
EsoCap’s novel targeted application platform is designed to increase mucosal contact time and esophageal drug deposition. The EsoCap technology consists of a capsule containing a thin mucoadhesive film loaded with an active pharmaceutical ingredient (API).
